ADVANCED MARKER DISCOVERY SL

Their core work

AMADIX is a Spanish biotech SME based in Valladolid that develops non-invasive blood-based diagnostic kits for early detection of colorectal cancer. Their work centers on discovering and validating biomarkers that identify cancer and pre-malignant lesions before symptoms appear, offering an alternative to colonoscopy screening. The company builds both the laboratory assays and the clinical risk-scoring models needed to move these tests toward commercial use. They are a clinical-stage diagnostics company, not a service lab — their output is a product intended for hospital and primary-care screening programs.

What they specialise in

How they've shifted over time

In their first H2020 project (ColoFast, 2017–2021), AMADIX concentrated on building and clinically validating a physical non-invasive diagnostic kit — a classic IVD product-development effort backed by a large SME-2 grant. By 2020 (AMX DATA), the focus broadened from the kit itself toward understanding which patients are at risk and why, including premalignant lesions. The trajectory suggests a move from a single-product play toward a more complete screening proposition that combines the test with risk stratification.

They appear to be layering risk-factor analytics on top of their diagnostic kit, which positions them for partnerships with hospitals, screening programs, and data-oriented health-tech players.

How they like to work

AMADIX has coordinated both of its H2020 projects, showing they are comfortable leading their own product development rather than riding along as a minor partner. The CORDIS record here lists zero consortium partners, which typically reflects the single-beneficiary SME Instrument model they used for ColoFast rather than a lack of collaborators in practice. Expect to work with them as the driving company, not as one voice in a large consortium.

Formal H2020 partner data is effectively empty because both projects were SME-instrument style single-beneficiary grants. Their real-world network (clinical sites, investors, distributors) is not visible from CORDIS alone.

What sets them apart

AMADIX is one of the few Spanish SMEs to secure a full SME-2 grant (EUR 2.8M) specifically for a colorectal cancer diagnostic — a signal that EU evaluators saw both clinical credibility and commercial potential. Unlike academic groups that stop at biomarker papers, AMADIX is productising: kit, clinical validation, and risk model under one roof. For a partner, this means you are dealing with a company that is building something to sell, not a lab looking for publications.

Highlights from their portfolio

• ColoFast
  Their flagship EUR 2.8M SME-2 project covering development and clinical validation of a non-invasive colorectal cancer detection kit.
• AMX DATA
  A smaller 2020 grant that expands the company from a single diagnostic kit toward risk-factor analytics for colorectal cancer and premalignant lesions.